drugset
drugset / Trial / NCT07076108

Oral Vitamin C Administration on Erythropoietin Dosing Requirement in End-Stage Renal Disease Patients on Regular Hemodialysis

NCT07076108 ↗

Completed 60 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

The study aimed to evaluate the safety and efficacy of oral vitamin C administration on erythropoietin dosing requirement in end-stage renal disease patients on regular hemodialysis.

Timeline

Start
2019-08-01
Primary completion
2024-04-28
Completion
2024-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 250 mg Oral
Subject Vitamin C Other / unclassified 500 mg Oral

Indications

end stage renal failure